Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Active rheumatoid arthritis (RA) diagnosed after the age of 16~* Currently taking methotrexate~* 6 or more swollen joints and 6 or more tender/painful joints (from 28 joint count) and either Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or C-Reactive Protein (CRP) blood result of 10mg/L or more~* At least one of the following: documented history of positive rheumatoid factor (blood test), current presence of rheumatoid factor (blood test), radiographic erosion within 12months prior to study enrolment, presence of serum anti-cyclic citrullinated peptide antibodies (blood test)~Exclusion Criteria:~* Females who are pregnant or breast feeding~* Poorly controlled hypertension~* Liver disease or significant liver function test abnormalities~* Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders~* Recent or significant cardiovascular disease~* Significant active or recent infection including tuberculosis~* Previous failure to respond to anakinra or previous treatment with biological agent (other than TNF alpha antagonists including rituximab, abatacept and tocilizumab)~* Severe renal impairment~* Neutropenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dosing Regimen A (Type: EXPERIMENTAL): Oral Treatment
- Dosing Regimen B (Type: EXPERIMENTAL): Oral Treatment
- Dosing Regimen C (Type: PLACEBO_COMPARATOR): Oral Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).